Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


04.06.2018

1 AJR Am J Roentgenol
2 Anticancer Res
4 BJU Int
3 BMC Cancer
1 Clin Cancer Res
1 Endocrinology
1 Eur J Radiol
3 Eur Urol
1 Int J Oncol
2 J Clin Oncol
2 J Nucl Med
2 J Urol
5 JAMA
1 Mod Pathol
1 Nat Rev Urol
1 Oncogene
3 Oncology (Williston Park)
2 PLoS One
1 Proc Natl Acad Sci U S A
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. SI Y, Liu RB
    Diagnostic Performance of Monoexponential DWI Versus Diffusion Kurtosis Imaging in Prostate Cancer: A Systematic Review and Meta-Analysis.
    AJR Am J Roentgenol. 2018 May 29:1-11. doi: 10.2214/AJR.17.18934.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. JURECEKOVA J, Drobkova H, Sarlinova M, Babusikova E, et al
    The Role of Interleukin-6 Polymorphism (rs1800795) in Prostate Cancer Development and Progression.
    Anticancer Res. 2018;38:3663-3667.
    PubMed     Text format     Abstract available

  3. ACUNA UM, Mo S, Zi J, Orjala J, et al
    Hapalindole H Induces Apoptosis as an Inhibitor of NF-kB and Affects the Intrinsic Mitochondrial Pathway in PC-3 Androgen-insensitive Prostate Cancer Cells.
    Anticancer Res. 2018;38:3299-3307.
    PubMed     Text format     Abstract available


    BJU Int

  4. SZARVAS T, Sevcenco S, Modos O, Keresztes D, et al
    MMP-7, sFas and FasL serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14415.
    PubMed     Text format     Abstract available

  5. KOVAC E, Vertosick EA, Sjoberg DD, Vickers AJ, et al
    Effects of Pathologic Upstaging or Upgrading on Metastasis and Cancer-Specific Mortality in men with Clinical Low-risk Prostate Cancer.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14418.
    PubMed     Text format     Abstract available

  6. OTTI VC, Miller C, Powell RJ, Thomas RM, et al
    The diagnostic accuracy of multiparametric MRI prior to biopsy in the detection of prostate cancer.
    BJU Int. 2018 May 27. doi: 10.1111/bju.14420.
    PubMed     Text format     Abstract available

  7. BANCROFT EK, Saya S, Page EC, Myhill K, et al
    The psychosocial impact of undergoing prostate cancer screening for men with BRCA1/2 mutations.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14412.
    PubMed     Text format     Abstract available


    BMC Cancer

  8. KASHIWABARA T, Suda S
    Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level >/= 50 ng/mL.
    BMC Cancer. 2018;18:619.
    PubMed     Text format     Abstract available

  9. HEINRICH MC, Gobel C, Kluth M, Bernreuther C, et al
    PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.
    BMC Cancer. 2018;18:612.
    PubMed     Text format     Abstract available

  10. MOSAAD E, Chambers K, Futrega K, Clements J, et al
    Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures.
    BMC Cancer. 2018;18:592.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  11. BLEE AM, He Y, Yang Y, Ye Z, et al
    TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-18-0653.
    PubMed     Text format     Abstract available


    Endocrinology

  12. HETTEL D, Zhang A, Alyamani M, Berk M, et al
    AR Signaling in Prostate Cancer Regulates a Feed-forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
    Endocrinology. 2018 May 29. pii: 5005852. doi: 10.1210/en.2018-00283.
    PubMed     Text format     Abstract available


    Eur J Radiol

  13. HANSEN NL, Koo BC, Warren AY, Kastner C, et al
    Sub-differentiating equivocal PI-RADS-3 lesions in multiparametric magnetic resonance imaging of the prostate to improve cancer detection.
    Eur J Radiol. 2017;95:307-313.
    PubMed     Text format     Abstract available


    Eur Urol

  14. LUGHEZZANI G, Buffi NM, Lazzeri M
    Diagnostic Pathway of Patients with a Clinical Suspicion of Prostate Cancer: Does One Size Fit All?
    Eur Urol. 2018 May 23. pii: S0302-2838(18)30361.
    PubMed     Text format    

  15. COOPERBERG MR, Erho N, Chan JM, Feng FY, et al
    The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.
    Eur Urol. 2018 May 28. pii: S0302-2838(18)30362.
    PubMed     Text format     Abstract available

  16. CONTEDUCA V, Gurioli G, De Giorgi U
    Re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press.
    Eur Urol. 2018 May 23. pii: S0302-2838(18)30363.
    PubMed     Text format    


    Int J Oncol

  17. ZHANG J, Shao S, Han D, Xu Y, et al
    High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF-kappaB signaling pathway.
    Int J Oncol. 2018 May 23. doi: 10.3892/ijo.2018.4420.
    PubMed     Text format     Abstract available


    J Clin Oncol

  18. BIBAULT JE, Blanchard P
    Treating Metastatic Prostate Cancer With Local Therapies: Is It Still Wishful Thinking?
    J Clin Oncol. 2018 Jun 1:JCO2017775429. doi: 10.1200/JCO.2017.77.5429.
    PubMed     Text format    

  19. CATTRINI C, Zanardi E, Boccardo F
    Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer.
    J Clin Oncol. 2018 Jun 1:JCO2018780031. doi: 10.1200/JCO.2018.78.0031.
    PubMed     Text format    


    J Nucl Med

  20. LARIMER BM, Dubois F, Bloch E, Nesti S, et al
    Specific (18)F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models is Facilitated by Pre-Binding to Sex Hormone Binding Globulin.
    J Nucl Med. 2018 May 31. pii: jnumed.118.208785. doi: 10.2967/jnumed.118.208785.
    PubMed     Text format     Abstract available

  21. THALGOTT M, Duwel C, Rauscher I, Heck MM, et al
    One-stop shop whole-body (68)Ga-PSMA-11 PET/MRI compared to clinical Nomograms for preoperative T- and N-Staging of High-Risk Prostate Cancer.
    J Nucl Med. 2018 May 24. pii: jnumed.117.207696. doi: 10.2967/jnumed.117.207696.
    PubMed     Text format     Abstract available


    J Urol

  22. WEINER AB, Tsai KP, Keeter MK, Victorson DE, et al
    The Influence of decision aids on prostate cancer screening preferences: A randomized survey study.
    J Urol. 2018 May 28. pii: S0022-5347(18)43270-3. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  23. RAYN KN, Bloom JB, Gold SA, Hale GR, et al
    Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms in Predicting Adverse Pathology in Prostate Cancer.
    J Urol. 2018 May 28. pii: S0022-5347(18)43271-5. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    JAMA

  24. FENTON JJ, Weyrich MS, Durbin S, Liu Y, et al
    Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2018;319:1914-1931.
    PubMed     Text format     Abstract available

  25. LOEB S, Byrne N, Makarov DV, Lepor H, et al
    Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015.
    JAMA. 2018 May 15. pii: 2681802. doi: 10.1001/jama.2018.5616.
    PubMed     Text format    

  26. CARTER HB
    Prostate-Specific Antigen (PSA) Screening for Prostate Cancer: Revisiting the Evidence.
    JAMA. 2018;319:1866-1868.
    PubMed     Text format    

  27. JIN J
    Screening for Prostate Cancer.
    JAMA. 2018;319:1946.
    PubMed     Text format    

  28. GROSSMAN DC, Curry SJ, Owens DK, Bibbins-Domingo K, et al
    Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2018;319:1901-1913.
    PubMed     Text format     Abstract available


    Mod Pathol

  29. KAUR HB, Guedes LB, Lu J, Maldonado L, et al
    Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer.
    Mod Pathol. 2018 May 30. pii: 10.1038/s41379-018-0083.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  30. MOUL JW
    Yes or no to local therapy for oligometastatic prostate cancer?
    Nat Rev Urol. 2018 May 23. pii: 10.1038/s41585-018-0028.
    PubMed     Text format    


    Oncogene

  31. PARK JJ, Park MH, Oh EH, Soung NK, et al
    The p21-activated kinase 4-Slug transcription factor axis promotes epithelial-mesenchymal transition and worsens prognosis in prostate cancer.
    Oncogene. 2018 May 30. pii: 10.1038/s41388-018-0327.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  32. CASTRO-ALONSO FJ, Dominguez-Pineda J, Rosales-Sotomayor G, Flaig TW, et al
    Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors.
    Oncology (Williston Park). 2018;32:243-6.
    PubMed     Text format    

  33. ISAACSSON VELHO P, Eisenberger MA
    Point: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer.
    Oncology (Williston Park). 2018;32:223-6.
    PubMed     Text format    

  34. JONES RJ
    Counterpoint: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer.
    Oncology (Williston Park). 2018;32:223.
    PubMed     Text format    


    PLoS One

  35. SCHWEIZER MT, Haugk K, McKiernan JS, Gulati R, et al
    A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
    PLoS One. 2018;13:e0198389.
    PubMed     Text format     Abstract available

  36. MARU S, Uchino H, Osawa T, Chiba S, et al
    Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy.
    PLoS One. 2018;13:e0197252.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  37. CHEN Z, Wu D, Thomas-Ahner JM, Lu C, et al
    Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
    Proc Natl Acad Sci U S A. 2018 May 29. pii: 1718811115.
    PubMed     Text format     Abstract available


    Urology

  38. MEDINA LG, Cacciamani GE, Hernandez A, Landsberger H, et al
    Robotic Management of Recto-Urethral Fistulas after Focal Treatment for Prostate Cancer.
    Urology. 2018 May 22. pii: S0090-4295(18)30469.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: